A5028718468- Milk Quality and Mastitis in Dairy Cows
- Cancer Treatment and Pharmacology
- Musculoskeletal synovial abnormalities and treatments
- Microtubule and mitosis dynamics
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Infant Nutrition and Health
- Cell Adhesion Molecules Research
- Plant and Fungal Interactions Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Effects of Environmental Stressors on Livestock
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Animal Behavior and Welfare Studies
- Microbial infections and disease research
- Reproductive Physiology in Livestock
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Immune Response and Inflammation
- Breast Cancer Treatment Studies
- Animal Diversity and Health Studies
Daiichi Sankyo (United States)
2014-2023
Hudson Institute
2023
John Wiley & Sons (United States)
2023
Liechtenstein Institute
2023
Columbus Oncology and Hematology Associates
2021
Istituto Oncologico Veneto
2015
University of Turin
2015
Poznan University of Medical Sciences
2015
Asklepios Fachkliniken München-Gauting
2015
Daiichi Sankyo (Germany)
2014
Two point mutations were identified within the gene encoding bovine CD18 in a Holstein calf afflicted with leukocyte adhesion deficiency (LAD). One mutation causes an aspartic acid to glycine substitution at amino 128 (D128G) highly conserved extracellular region of this glycoprotein, where several have been found cause human LAD. The other is silent. Twenty calves clinical symptoms LAD tested, and all homozygous for D128G allele. In addition, two allele during widespread DNA testing, both...
Purpose Tivantinib, a MET receptor tyrosine kinase inhibitor, demonstrated increased anticancer activity in preclinical and early clinical studies when combined with erlotinib. Our study aimed to confirm efficacy safety of the combination previously treated patients non–small-cell lung cancer (NSCLC). Patients Methods advanced nonsquamous NSCLC one two systemic regimens, including platinum doublet, were randomly assigned at 1:1 ratio receive erlotinib 150 mg daily plus oral tivantinib 360...
Eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor, is structurally simplified, synthetic analog of the marine natural product halichondrin B. This open-label, single-arm, phase II study evaluated efficacy and tolerability eribulin in heavily pretreated patients with metastatic breast cancer (MBC).MBC who were previously treated an anthracycline taxane received (1.4 mg/m(2)) as 2- to 5-minute intravenous (IV) infusion on days 1, 8, 15 28-day cycle. Because neutropenia (at...
Objective: To study antimicrobial resistance in zoonotic bacteria isolated from food animals different countries using uniform methodology.
The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with novel mechanism action, were evaluated in patients locally advanced or metastatic breast cancer previously treated an anthracycline, taxane, capecitabine.Eligible this single-arm, open-label phase II study received (1.4 mg/m(2)) administered as 2- to 5-minute intravenous infusion on days 1 8 21-day cycle. primary end point was objective response rate (ORR) assessed by independent review.Of...
Generation of inflammatory mediators and leukocyte recruitment to infection at an epithelial surface were studied during Escherichia coli-induced mastitis. One uninfected gland each eight midlactation cows was challenged with only 30 CFU E. coli McDonald strain 487, a serum-resistant isolate from cow Bacteria grew logarithmically the first 10 12 h after challenge, reaching concentrations more than 10(5) CFU/ml no detectable host response this time. An intense reaction began approximately...
Abstract Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is structurally simplified, synthetic analogue of halichondrin B that acts via mechanism distinct from conventional tubulin-targeted agents. This phase I study determined the maximum tolerated dose (MTD) and pharmacokinetics eribulin administered on 3 4 week schedule in patients with advanced solid malignancies. Experimental Design: Patients received (1-hour i.v. infusion) days 1, 8, 15 28-day cycle....
Abstract Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389), a halichondrin B analogue, administered every 21 days in patients with advanced solid tumors. Experimental Design: Eribulin was given as 1-hour infusion at doses 0.25, 0.5, 1, 2, 2.8, 4 mg/m2. The MTD identified using an accelerated titration design. were evaluated plasma urine first dose. Results: Twenty-one enrolled. At mg/m2, three experienced...
Abstract Objective To define causes of increased susceptibility to coliform mastitis after parturition. Animals 12 healthy Holstein cows assigned 2 groups. Group-1 (n = 6) had calved between 6 and 10 days earlier. Group-2 were in midlactation. Procedure Cows from each group paired challenge exposed with Escherichia coli 1 mammary gland. Mastitis severity was determined by bacterial concentration milk, pyrexia, milk production. Measures host defense neutrophil chemotaxis, adhesion molecule...
SUMMARY The role of interleukin-1 ( il -1), interleukin-6 - 6), and tumor necrosis factor α during endotoxin-induced mastitis in cows was characterized. Six had 10 μg Escherichia coli lipopolysaccharide infused into 1 mammary gland. Three other served as nontreated controls. Within 1.5 to 2.5 hours after infusion, endotoxin caused obvious edema the gland increased serum albumin concentration milk glands 6 times. Milk somatic cell count began increase 3 5 infusion all treated glands. At 7...
// Lorenza Rimassa 1 , Giovanni Abbadessa 2 Nicola Personeni 1,3 Camillo Porta 4 Ivan Borbath 5 Bruno Daniele 6 Stefania Salvagni 7 Jean-Luc Van Laethem 8 Hans Vlierberghe 9 Jörg Trojan 10 Enrico N. De Toni 11 Alan Weiss 12 Steven Miles 13 Antonio Gasbarrini 14 Monica Lencioni 15 Maria E. Lamar Yunxia Wang Dale Shuster 16 Brian Schwartz and Armando Santoro 1,17 Humanitas Cancer Center, Clinical Research Rozzano, Milan, Italy ArQule, Burlington, MA, USA 3 Department of Medical...
Udder preparations that wet both udder surfaces and teats had the highest standard plate count in milk compared with methods only. Physical action of cleaning a dry towel lowered bacterial wetting teats. Methods resulting lowest counts were use water hose, towel, or premilking disinfectant teat dip followed by drying paper towels. Counts coliform Staphylococcus sp. similar trends. In most comparisons, addition wash sanitizer was marginal no benefit. Standard rinses after preparation...
Background The objective of this study was to report on the long‐term effects pexidartinib tenosynovial giant cell tumor (TGCT). Methods This a pooled analysis encompassing 3 pexidartinib‐treated TGCT cohorts: 1) phase 1 extension (NCT01004861; 1000 mg/d; n = 39), 2) ENLIVEN patients randomized (1000 mg/d for 2 weeks and then 800 61), 3) crossover (NCT02371369; 30). Eligible were 18 years old or older had histologically confirmed that unresectable symptomatic. Efficacy endpoints included...
Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib.Hepatic adverse reactions (ARs) were by type and magnitude liver test abnormalities, classified as (a) isolated aminotransferase elevations (alanine [ALT] or aspartate [AST], without significant alkaline phosphatase [ALP] bilirubin elevations), (b) mixed cholestatic hepatotoxicity (increase ALP ALT/AST...
Production of inflammatory cytokines and concentrations growth hormone insulin-like factor-I (IGF-I) were studied during experimental Escherichia coli mastitis to determine their potential involvement in reduced animal performance infectious disease. During the first 10 14 hr after intramammary infusion E. coli, bacteria multiplied maximum levels 10(4)-10(9) cfu/ml milk with no clinical signs mastitis. A rapid intense response, characterized by udder swelling, increased bovine serum albumin...